Home » FDA Panel Sets Date To Review Sapien for High-Risk Cohort
FDA Panel Sets Date To Review Sapien for High-Risk Cohort
The FDA’s advisory panel has proposed a review of Edward Lifesciences’ premarket approval (PMA) application for its Edwards Sapien transcatheter heart valve on June 13.
CardiovascularBusiness
CardiovascularBusiness
Upcoming Events
-
07May
-
14May
-
30May